Following a full submission
AWMSG advice |
|
| Status: Superseded | |
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED AUGUST 2025. Refer to TA1093: Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. |
|
Medicine details |
|
| Medicine name | idebenone (Raxone®) |
| Formulation | 150 mg film-coated tablet |
| Reference number | 807 |
| Indication | Treatment of visual impairment in adolescent and adult patients with Leber’s hereditary optic neuropathy |
| Company | Chiesi Ltd |
| BNF chapter | Eye |
| Assessment type | Full |
| Status | Superseded |
| Advice number | 0521 |
| NMG meeting date | 04/11/2020 |
| AWMSG meeting date | 10/03/2021 |
| Date of issue | 17/03/2021 |
| NICE guidance | |
| Commercial arrangement | WPAS |